Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3801-3820 of 3,900 trials

Obesity Treatment: Orforglipron Tablet Study

We are investigating how well a new daily tablet helps people with obesity or overweight, both with and without type 2 diabetes, in reducing weight and improving blood sugar levels compared to a placebo.

ObesityOverweightType 2 Diabetes1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

HIV Treatment: MK-4646 Study

We are testing a new medication, MK-4646, for people living with HIV. The study aims to see how well it works in managing the virus compared to current treatments.

HIV Infection6-12 monthsSafety phase (I)Infectious Diseases

Cancer Prevention in Lynch Syndrome: Dendritic Cell Therapy

We are testing a new treatment using dendritic cells to help prevent cancer in people with Lynch Syndrome. This study aims to assess its safety and effectiveness in this high-risk group.

Lynch Syndrome>2 yearsSafety phase (I)Internal MedicineOncology

Zelenectide Pevedotin for Advanced Non-small Cell Lung Cancer

We are studying a new treatment for patients with advanced or metastatic non-small cell lung cancer that has NECTIN4 amplification. The goal is to see how well it works and how safe it is for those who have already been treated.

Advanced Non-small Cell Lung Cancer1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Ovarian Cancer: COM701 Treatment Study

We are testing the safety and effectiveness of COM701 for patients with relapsed platinum-sensitive ovarian cancer. The study aims to see if it can help patients maintain their health without cancer progression.

Ovarian CancerRecurrent Ovarian Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGynecology and ObstetricsOncology

Multiple Sclerosis: Subcutaneous vs. Intravenous Ublituximab

We are studying how a new subcutaneous injection of ublituximab compares to the intravenous version for people with relapsing multiple sclerosis. The goal is to evaluate its safety and effectiveness in managing the condition.

Relapsing Multiple SclerosisConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurology

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

IVF/ICSI: Low Dose hCG Priming for Women with Diminished Ovarian Reserve

We are investigating whether low dose hCG priming can help women with diminished ovarian reserve retrieve more eggs during IVF/ICSI. This study aims to confirm earlier findings that suggest a significant increase in egg retrieval.

Infertility Due to Diminished Ovarian Reserve>2 yearsConfirmation phase (III)Standard MedicinesGynecology and Obstetrics

Birth Control Study: Levonorgestrel Tablet

We are investigating whether the Levonorgestrel tablet can still prevent ovulation despite planned delays in taking the pill. This study is for individuals interested in understanding the reliability of this contraceptive method.

Ovulation Inhibition6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Acromegaly: ALXN2420 Treatment Study

We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.

Acromegaly1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinology

Advanced Solid Tumors: S095035 Treatment Study

We are investigating the safety and effectiveness of S095035, alone and with TNG462, for adults with advanced solid tumors that have a specific genetic deletion. This study aims to find the best dose and assess how well the treatment works.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

Acute Ischemic Stroke and Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Gastrointestinal Tumors: OncoGreen Imaging Study

We are testing a new imaging technique using OncoGreen to help surgeons better visualize tumors during surgery. This study is for patients with gastrointestinal tumors who are having surgery to remove their tumors.

Digestive System Tumors>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterologyInternal MedicineOncology

Atrial Fibrillation: Amiodarone Administration Study

We are comparing intravenous and enteral amiodarone in critically ill patients with new-onset atrial fibrillation. The goal is to see which method is more effective in restoring normal heart rhythm and improving overall health.

Atrial Fibrillation with Rapid Ventricular Response≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lactose Intolerance Diagnosis: LacTEST for Children

We are studying the LacTEST to see if it accurately diagnoses lactose intolerance in children aged 5 to 11. The trial will also check the test's safety and whether a shorter urine collection time is effective.

Lactose Intolerance≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyPediatrics

Advanced Solid Tumors: EP102 Treatment

We are testing the safety and effectiveness of EP102 in patients with advanced solid tumors. This study aims to see if it can provide better treatment options for these patients.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology